MRUS Overview

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

Wall Street analysts forecast MRUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRUS is97.71 USD with a low forecast of 92.00 USD and a high forecast of 112.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Merus NV revenue for the last quarter amounts to 12.15M USD, increased 3.21

Merus NV. EPS for the last quarter amounts to -1.26 USD, decreased -13.70

Merus NV (MRUS) has 260 emplpoyees as of March 14 2026.

Today MRUS has the market capitalization of 4.06B USD.